J
Julia Hambach
Researcher at University of Hamburg
Publications - 12
Citations - 443
Julia Hambach is an academic researcher from University of Hamburg. The author has contributed to research in topics: Antibody & CD38. The author has an hindex of 5, co-authored 8 publications receiving 287 citations.
Papers
More filters
Journal ArticleDOI
Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.
TL;DR: Recent developments and perspectives for applications of nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics are discussed.
Journal ArticleDOI
Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs).
Julia Hambach,Kristoffer Riecken,Sophia Cichutek,Kerstin Schütze,Birte Albrecht,Katharina Petry,Jana Larissa Röckendorf,Natalie Baum,Nicolaus Kröger,Timon Hansen,Gunter Schuch,Friedrich Haag,Gerhard Adam,Boris Fehse,Peter Bannas,Friedrich Koch-Nolte +15 more
TL;DR: This work cloned retroviral expression vectors for CD38-specific Nb-CARs and established luminescence and flow-cytometry CAR-dependent cellular cytotoxicity assays (CARDCCs), demonstrating efficacy of Nb -CARs in vitro and potential clinical efficacy in vivo.
Journal ArticleDOI
CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells.
Kerstin Schütze,Katharina Petry,Julia Hambach,Niklas Schuster,William Fumey,Levin Schriewer,Jana Larissa Röckendorf,Stephan Menzel,Birte Albrecht,Friedrich Haag,Catelijne Stortelers,Peter Bannas,Friedrich Koch-Nolte +12 more
TL;DR: The CD38-specific biparatopic heavy chain antibodies described here represent potential new powerful therapeutics for treatment of multiple myeloma and underscore the advantage of nanobodies vs. pairs of VH and VL domains for constructing bispecific antibodies.
Journal ArticleDOI
Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies.
Levin Schriewer,Kerstin Schütze,Katharina Petry,Julia Hambach,William Fumey,Julia Koenigsdorf,Natalie Baum,Stephan Menzel,Björn Rissiek,Kristoffer Riecken,Boris Fehse,Jana Larissa Röckendorf,Joanna Schmid,Birte Albrecht,Hans O. Pinnschmidt,Francis Ayuk,Nicolaus Kröger,Mascha Binder,Gunter Schuch,Timon Hansen,Friedrich Haag,Gerhard Adam,Friedrich Koch-Nolte,Peter Bannas +23 more
TL;DR: CD38-specific nanobody-based humanized IgG1 heavy chain antibodies mediate cytotoxicity against CD38-expressing hematological cancer cells in vitro, ex vivo and in vivo.
Journal ArticleDOI
Daratumumab and Nanobody-Based Heavy Chain Antibodies Inhibit the ADPR Cyclase but not the NAD+ Hydrolase Activity of CD38-Expressing Multiple Myeloma Cells.
Natalie Baum,Ralf Fliegert,Andreas Bauche,Julia Hambach,Stephan Menzel,Friedrich Haag,Peter Bannas,Friedrich Koch-Nolte +7 more
TL;DR: In this article, the NAD+ hydrolase CD38 is expressed at high levels on the cell surface of multiple myeloma (MM) cells and the effects of CD38-specific antibodies on these activities are assessed.